Full versus prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis

Not available.

[1]  K. Thorpe,et al.  Randomized trials of therapeutic heparin for COVID‐19: A meta‐analysis , 2021, Research and Practice in Thrombosis and Haemostasis.

[2]  Marcelo A. Falappa,et al.  Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial , 2021, BMJ.

[3]  V. Jiménez‐Yuste,et al.  Therapeutic vs. prophylactic bemiparin in hospitalized patients with non-severe COVID-19 (BEMICOP): an open-label, multicenter, randomized trial , 2021, Thrombosis and Haemostasis.

[4]  J. Halperin,et al.  Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. , 2021, JAMA internal medicine.

[5]  R. Mehran,et al.  Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials , 2021, European heart journal. Cardiovascular pharmacotherapy.

[6]  Christopher M. Horvat,et al.  Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 , 2021, The New England journal of medicine.

[7]  Christopher M. Horvat,et al.  Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 , 2021, The New England journal of medicine.

[8]  Á. Avezum,et al.  Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial , 2021, The Lancet.

[9]  E. Kline-Rogers,et al.  Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication. , 2021, JAMA internal medicine.

[10]  A. Pazin-Filho,et al.  Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID) , 2020, Thrombosis Research.

[11]  J. Douketis,et al.  Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[12]  F. Violi,et al.  Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge , 2020, Thrombosis and Haemostasis.